title: Long-term follow-up of re-sting reactions in children with moderate to severe venom hypersensitivity.
abstract: Few data exists about re-sting reactions and their prognosis in children with moderate to severe venom hypersensitivity. The reasons behind not consenting to or prematurely ending venom immunotherapy (VIT) and the preparedness of children who refused or quit VIT for future moderate-severe systemic reaction (SR) to re-stings have not been studied. Data on children with moderate to severe SR after Hymenoptera stings was collected for a 17-year period using our database. A standardized questionnaire was administered to patients who accepted to be interviewed at the clinic. These patients were evaluated in terms of their preparedness for future moderate-severe SR to re-stings. A total of 55 children, 75 % of whom commenced on VIT, were included in the analysis. Different reasons exist for not consenting to VIT; the most common of which is living at a distance from the allergy center. There were no differences in terms of the number of re-stung patients (27.7 and 27.2 %, respectively) and moderate-severe SR (60 and 16.6 %, respectively) between children who prematurely ended or who did not consent to VIT and children who completed VIT. Sixty-four percent of the children who refused or discontinued VIT were not prepared for future moderate-severe SR to re-stings.
  
  
  CONCLUSIONS
  Long-term prognosis for re-sting reactions is good in children with moderate to severe SR to venoms. Some of the reasons behind refusing or discontinuing VIT may be related to quality of life issues. Preparedness of children who refused or discontinue VIT in emergencies is very low.
authors.affiliation: Department of Pediatric Allergy and Asthma, Gazi University School of Medicine, 06500, Besevler/Ankara, Turkey, theilbilge@yahoo.com.au.
authors.forename: Hacer Ilbilge
authors.initials: HI
authors.lastname: Ertoy Karagol
authors.forename: Arzu
authors.initials: A
authors.lastname: Bakirtas
authors.forename: Ozlem
authors.initials: O
authors.lastname: Yilmaz
authors.forename: Erdem
authors.initials: E
authors.lastname: Topal
authors.forename: Mustafa
authors.initials: M
authors.lastname: Arga
authors.forename: Mehmet Sadik
authors.initials: MS
authors.lastname: Demirsoy
authors.forename: Ipek
authors.initials: I
authors.lastname: Turktas
mesh_terms: D000818:Animals; D001514:Bee Venoms / Q000009:adverse effects* / Q000276:immunology; D002648:Child; D003888:Desensitization, Immunologic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006927:Hymenoptera; D006969:Hypersensitivity, Immediate / Q000628:therapy*; D007299:Insect Bites and Stings / Q000276:immunology / Q000628:therapy; D008297:Male; D055118:Medication Adherence; D011788:Quality of Life; D012008:Recurrence; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D016312:Treatment Refusal; D014862:Wasp Venoms / Q000009:adverse effects* / Q000276:immunology
chemical_list: D001514:Bee Venoms; D014862:Wasp Venoms